NCT06699836 - A Phase 2 Study of Leronlimab in Combination With TAS-102 + Bevacizumab in Previously Treated Participants With mCRC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 16, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

March 31, 2028

Conditions

Metastatic Colorectal Cancer (mCRC)

Interventions

DRUG

350 mg leronlimab

Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)

DRUG

700 mg leronlimab

Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)

Trial Locations (6)

RECRUITING

Fox Chase Cancer Center, Philadelphia

RECRUITING

Norton Cancer Institute, Brownsboro Hospital Campus, Louisville

RECRUITING

University of Nebraska Medical Center, Omaha

RECRUITING

City of Hope Orange County Lennar Foundation Cancer Center, Irvine

ACTIVE_NOT_RECRUITING

Pacific Hematology Oncology Associates, San Francisco

RECRUITING

Summit Cancer Center, Spokane